Full name

A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)

NCT Number
NCT06613698
Geography
US
Non-US
Locations

Canada, Italy, Japan, Republic of Korea, Spain, United Kingdom, United States

Primary Endpoints
  • Number of participants with adverse events (AEs) and serious adverse events (SAEs). Up to 8 weeks
  • Number of participants with potentially clinically relevant changes in electrocardiogram (ECG), vital signs, and clinical laboratory tests. Up to 8 weeks
  • Change from baseline in Liver Stiffness measurement (LSM) reduction using FibroScan® at Week 28 (kiloPascal). Baseline (Day 1) and up to Week 28
  • Change from baseline in model for end-stage liver disease (MELD) score reduction at Week 28. Baseline (Day 1) and up to Week 28
Order
0
Disease
ALD
Menu title
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease (STARLIGHT)
Version
NMA 2025
Phase
2
Status
Recruiting